Sun Pharmaceuticals Industries Ltd
ABOUT
Sun Pharmaceutical Industries Ltd is participated occupied with assembling, creating, and showcasing a large number of marked and conventional definitions and Dynamic Pharma Fixings (APIs). The organization and its auxiliaries have different assembling offices spread across the world with exchanging and other coincidental and related exercises stretching out to the worldwide market. It is the biggest drug organization in India.
KEY POINTS
Product Offerings
The organization creates a thorough and different arrangement of conventional and specialty drugs focusing on a wide range of persistent and intense therapies. Its item portfolio incorporates generics, marked generics, strength, challenging-to-make innovation escalated items, antiretrovirals, APIs, and intermediates. It offers prescriptions in all types of doses for example injectables, showers, balms, creams, fluids, tablets, and containers.
Indian Branded Generics (~31% of revenues)
The organization is the biggest pharma organization in India with an 8.2% piece of the pie as of FY21. It has serious areas of strength for a situating with 28 of its brands present in the main 300 pharma brands in the country. It additionally has a low item focus with its main 10 brands contributing just ~20% of its Indian income. It has serious areas of strength for strength with ~11,000 individuals in its outreach group. It sells items across 15+ helpful classifications with a predominant piece of the pie in key remedial regions like cardiology, neuropsychiatry, gastroenterology, and others.
US Business (~30% of revenues)
The company entered the US pharma market in 1997 and has since established its position in the US generics market. It focuses on Central Nervous System (CNS), dermatology, cardiology, oncology, and ophthalmic, segments in the USAIt has a wide basket of ~600 ANDAs (abbreviated new drug applications) & 60+ NDAs filed with USFDA and has ~500 ANDAs & 55 NDAs approved across multiple therapies.
Emerging Markets (~18% of revenues)
It is amongst the leading Indian pharma companies in Emerging markets and sells products in ~80 global markets with a focus on Romania, Russia, South Africa, Brazil, Mexico, and others. It also has local manufacturing units across Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria, and Russia. It sells products through a sales force of ~2,200 sales representatives.
Rest of World Business (~15% of revenues)
The company is among the leading Indian pharma companies operating in Western Europe, Canada, Japan, Australia, and other markets as well. It has established local manufacturing units in Canada, Japan, Australia, Israel, and Hungary and follows a distribution-led growth model in these markets.
It acquired a significant presence in Japan by acquiring 14 established Japanese brands from Novartis in 2016 and by acquiring Pola Pharma in Japan in 2019.
Sun Pharmaceuticals Industries Ltd Fundamental
APIs Business (~6% of revenues)
The company manufactures and sells Active Pharmaceutical Ingredients across various countries. It has ~480 USDMF (drug master files) filed with ~365 approved to date. Its product portfolio includes ~300 different APIs. The business is strategically important for the company as it provides opportunities for strong backward integration for formulations business.
Sun Pharmaceuticals Industries Ltd
International Presence
The company is a global pharmaceutical player with a presence in countries such as the USA, Europe, Canada, Japan, Australia, New Zealand, and various other markets including emerging pharma markets. In FY21, the company earned ~67% of revenues from international business compared to ~73% in FY17.
Manufacturing Capabilities
Presently, the company owns and operates 44 manufacturing facilities/ sites across the world either directly or through subsidiaries/ associates of JVs. It operates 30 plants for the manufacturing of formulations and 14 plants for APIs. 24 of the total plants are located in India while the rest are located in other countries across the world.
R&D Capabilities
The company undertakes R&D activities through its own R&D labs. Its 6 major labs are located in India, Israel, Canada, and the USA. It has capabilities across generics, finished dosage development, biological support, chemistry, and new drug development and has employed ~2,600 employees for R&D globally
Over the last 5 years, the company has spent ~6% of total revenues on R&D with ~2,000 patents filed. Over the last decade, it has spent ~17,000 crores on Research & Development.
Past Acquisitions
Over the past decade, the company has acquired 6 companies which helped it significantly to grow its scale of operations. Past acquisitions include Dusa Pharma, Taro Pharma, URL Pharma, Ranbaxy Laboratories, Biosintez, and Pola Pharma.
SUN PHARMA Share Price Today:
SUN PHARMA's last traded price was up 0.05% to Rs 944.55 on the BSE. On the NSE, SUN PHARMA's last traded price was down 0.44% to Rs 944 The total volume of shares traded was 1.857m
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.3%. And the benchmark S&P BSE SENSEX was at 58,348.7 (up 0.5%).
Over the last 30 days, the SUN PHARMA share price is up 6.23%. And over the last year, SUN PHARMA's share price is up 15.1%.
The current market capitalization of SUN PHARMA stands at Rs ₹ 229,05.cr For more information, check out the list of the top 100 companies in India in terms of market cap.
As of June 2022, promoter pledging in SUN PHARMA stands at 4.04%. To know more, check out the latest shareholding pattern of SUN PHARMA.
To know more
No comments:
Post a Comment